Apolipoprotein E allelic frequency altered in women with early-onset breast cancer

Breast Cancer: Basic and Clinical Research

Volumn 4, Issue 1, 2010, Pages 43-48

  Porrata Doria, Tirtsa ^a   Matta, Jaime L ^a   Acevedo, Summer F ^a,b  

^a and Toxicology ^*  (Puerto Rico)

^b PONCE SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Apoe; Breast cancer; Early onset; Puerto rican; Risk factor

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST CANCER; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; CIGARETTE SMOKING; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; GENE FREQUENCY; GENOTYPE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARRIAGE; PREDICTION; PREGNANCY; PUERTO RICO; RISK FACTOR; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 77955478702     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.1177/117822341000400005     Document Type: Article

References (28)

1. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163:49-56.
2. De Angelis R, Tavilla A, Verdecchia A, et al. Breast cancer survivors in the United States: geographic variability and time trends, 2005-2015. Cancer. 2009;115:1954-66.
3. Ripperger T, Gadzicki D, Meindl A, Schlegelberger B. Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet. 2009;17:722-31.
4. Yaylim I, Bozkurt N, Yilmaz H, Isbir T, Isik N, Arikan S. The apolipoprotein E epsilon 4 allele is not a risk factor for Turkish breast cancer patients. Cancer Genet Cytogenet. 2003;146:86-7.
5. Niemi M, Kervinen K, Kiviniemi H, et al. Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. J Epidemiol Community Health. 2000;54:938-9.
6. Zunarelli E, Nicoll JA, Migaldi M, Trentini GP. Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome. Breast Cancer Res Treat. 2000;63:193-8.
7. Chang NW, Chen DR, Wu CT, et al. Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan. Breast Cancer Res Treat. 2005;90:257-61.
8. Moore RJ, Chamberlain RM, Khuri FR. Apolipoprotein E and the risk of breast cancer in African-American and non-Hispanic white women. A review. Oncology. 2004;66:79-93.
9. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-30.
10. Puerto Rico: Breast Cancer Incidence Rate per 100,000 Women. statehealthfacts. org. Kaiser Family Foundation., 2003.
11. Figueroa NR, De la Torre T, Ortiz KJ, Perez J, Torres ME. Cancer of the Breast Stat Fact Sheet Puerto Rico Central Cancer Registry. San Juan, PR: Puerto Rico Department of Health, 2008.
12. Phillips AA, Jacobson JS, Magai C, Consedine N, Horowicz-Mehler NC, Neugut AI. Cancer incidence and mortality in the Caribbean. Cancer Invest. 2007;25:476-83.
13. Ho GY, Figueroa-Valles NR, De La Torre-Feliciano T, et al. Cancer disparities between mainland and island Puerto Ricans. Rev Panam Salud Publica. 2009;25:394-400.
14. Martinez-Cruzado JC, Toro-Labrador G, Ho-Fung V, et al. Mitochondrial DNA analysis reveals substantial Native American ancestry in Puerto Rico. Hum Biol. 2001;73:491-511.
15. Martinez-Cruzado JC, Toro-Labrador G, Viera-Vera J, et al. Reconstructing the population history of Puerto Rico by means of mtDNA phylogeographic analysis. Am J Phys Anthropol. 2005;128:131-55.
16. Szklo M, Nieto FJ. Epidemology. Beyond the Basics. Second Edition edn. Boston: Jones and Bartlett Publishers, 2007.
17. Risendal B, Hines LM, Sweeney C, et al. Family history and age at onset of breast cancer in Hispanic and non-Hispanic white women. Cancer Causes Control. 2008;19:1349-55.
18. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545-8.
19. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one- stage PCR. Lancet. 1991;337:1158-9.
20. Moysich KB, Freudenheim JL, Baker JA, et al. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol Carcinog. 2000;27:2-9.
21. Romaguera J, Ortiz AP, Roca FJ, Colon G, Suarez E. Factors associated with metabolic syndrome in a sample of women in Puerto Rico. Menopause. 2010;2:388-39.
22. Liberopoulos E, Karabina SA, Tselepis A, et al. Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? Oncology. 2002;62:115-20.
23. Tempfer CB, Riener EK, Hefler LA, Huber JC, Muendlein A. DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy. Fertil Steril. 2004;82:132-7.
24. Chang NW, Chen FN, Wu CT, Lin CF, Chen DR. Apolipoprotein E4 allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients. Clin Chim Acta. 2009;401:144-7.
25. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612-9.
26. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID, Jatoi I. Racial disparities in breast cancer outcome: insights into host-tumor interactions. Cancer. 2007;110:1880-8.
27. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302:1685-92.
28. Justenhoven C, Hamann U, Schubert F, et al. Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat. 2008;108:137-49.